Table 4.
Results of the studies assessing the efficacy of GnRHa given before and during chemotherapy in HSCT recipients in terms of ovarian function and fertility preservation.
| Reference | No of patients | Previous Cxt | Type of HSCT | Type of disease | Results |
|---|---|---|---|---|---|
| Blumenfeld, 2012 | 83 | Allo/auto | Various | 18/47 in GnRHa group vs 4/36 in control group | |
| 33 | Auto | Lymphoma | 14/21 in GnRHa group vs 2/11 in control group | ||
| Cheng, 2012 | 44 | Yes (42/44) | Allo/auto | Various | 7/44 |
| 29 | Allo | Allo HSCT | 2/29, P = 0.04 | ||
| 15 | Auto HSCT | 5/15 | |||
| Pup, 2014 | 17 | Auto | Lymphoma | 5/17 | |
| Phelan, 2016 | 17 (7 received GnRHa) | Yes | Auto/allo | Various | 3/7 |
| Demesteere, 2016 | 10 (3 received GnRHa) | No | Auto | Lymphoma | 2/3 in GnRHa group vs 4/7 in control group |
HSCT, hematopoietic stem cell transplantation.
This work is licensed under a